A Phase 1 interventional study of Cenvacibart in Healthy Volunteers, sponsored by Regeneron Pharmaceuticals. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment
This trial is being done in non-obese healthy participants to compare two different forms of cenvacibart.
The main goal of the trial is to learn about the trial medicine and how it is absorbed, modified, and removed from the body.
The trial will look at:
Regeneron Pharmaceuticals is the lead sponsor of 409 studies on the registry; 92 are open to participants now.
Of its 123 completed or terminated interventional studies of FDA-regulated products, 79 (64%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
Drug: Cenvacibart
Drug: Cenvacibart
Administered per the protocol
Also known as: REGN7508
Area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast)
Time frame: Up to approximately day 57
Maximum observed concentration (Cmax)
Time frame: Up to approximately day 57
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Time frame: Up to approximately day 100
Severity of TEAEs
Time frame: Up to approximately day 100
Occurrence of Anti-Drug Antibody (ADA) to cenvacibart
Time frame: Up to approximately day 57
Magnitude of ADA to cenvacibart
Time frame: Up to approximately day 57
No study locations are listed for this record.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cenvacibart